A Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study With Open-Label Follow-up to Investigate the Effect of IM Testosterone Undecanoate on Biochemical and Anthropometric Characteristics of Metabolic Syndrome in Hypogonadal Men
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Testosterone undecanoate (Primary)
- Indications Hypogonadism; Metabolic syndrome
- Focus Pharmacodynamics
- 13 May 2010 Interim results were presented at the 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy).
- 09 Jul 2008 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History